Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design.
Lucia De Prado Gomez PharmD MScIan PavordWilliam BusseChristopher E BrightlingMichael E WechslerKlaus F RabeMei ZhangJun XingJuby A Jacob-NaraPaul J RowePublished in: ERJ open research (2023)
ATLAS is the first trial assessing the effect of a biologic on LFD, designed to establish the role of dupilumab in prevention of long-term loss of lung function and its potential effect on disease modification, which may provide unique insights into asthma pathophysiology, including predictive and prognostic factors of LFD.